Llwytho...
The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRAS(Q61K) melanoma
Structure-based drug repositioning in addition to random chemical screening is now a viable route to rapid drug development. Proteochemometric computational methods coupled with kinase assays showed that mebendazole (MBZ) binds and inhibits kinases important in cancer, especially both BRAF(WT) and B...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Oncotarget |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Impact Journals LLC
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5355037/ https://ncbi.nlm.nih.gov/pubmed/28157711 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14990 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|